Transplantation in Atypical Hemolytic Uremic Syndrome

 

 Permissions and Reprints

ABSTRACT

Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by overactivation of complement. Recurrence following renal transplantation is determined by a genetic predisposition. Genetic screening of all individuals with aHUS should be performed prior to listing for transplantation. Individuals with isolated mutations in MCP have a low risk of recurrence and may be considered for kidney transplantation alone. In individuals with CFH and CFI mutations, the risk of recurrence following renal transplantation is high. Combined liver/kidney transplantation has been used successfully in individuals with CFH mutations following the introduction of perioperative plasma exchange; however, such a procedure is not without its risks. Liver/kidney transplantation has yet to be performed on individuals with CFI and C3 mutations but may be predicted to be successful. In individuals with CFH autoantibodies, a reduction in titer through plasma exchange and rituximab has been successful. Clinical trials of the complement C5 inhibitor eculizumab may improve prospects for isolated renal transplantation in individuals with complement protein mutations.

REFERENCES

• 1 Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes.  Annu Rev Med. 2008;  59 293-309
  CrossrefPubMedGoogle Scholar
• 2 Richards A, Buddles M R, Donne R L et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.  Am J Hum Genet. 2001;  68(2) 485-490
  CrossrefPubMedGoogle Scholar
• 3 Caprioli J, Bettinaglio P, Zipfel P F Itaslian Registry of Familial and Recurrent HUS/TTP et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.  J Am Soc Nephrol. 2001;  12(2) 297-307
  PubMedGoogle Scholar
• 4 Pérez-Caballero D, González-Rubio C, Gallardo M E et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.  Am J Hum Genet. 2001;  68(2) 478-484
  CrossrefPubMedGoogle Scholar
• 5 Dragon-Durey M A, Frémeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.  J Am Soc Nephrol. 2004;  15(3) 787-795
  CrossrefPubMedGoogle Scholar
• 6 Frémeaux-Bacchi V, Dragon-Durey M A, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.  J Med Genet. 2004;  41(6) e84
  CrossrefPubMedGoogle Scholar
• 7 Kavanagh D, Kemp E J, Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(7) 2150-2155
  CrossrefPubMedGoogle Scholar
• 8 Caprioli J, Noris M, Brioschi S International Registry of Recurrent and Familial HUS/TTP et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.  Blood. 2006;  108(4) 1267-1279
  CrossrefPubMedGoogle Scholar
• 9 Richards A, Kemp E J, Liszewski M K et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2003;  100(22) 12966-12971
  CrossrefPubMedGoogle Scholar
• 10 Noris M, Brioschi S, Caprioli J International Registry of Recurrent and Familial HUS/TTP et al. Familial haemolytic uraemic syndrome and an MCP mutation.  Lancet. 2003;  362(9395) 1542-1547
  CrossrefPubMedGoogle Scholar
• 11 Frémeaux-Bacchi V, Moulton E A, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2006;  17(7) 2017-2025
  CrossrefPubMedGoogle Scholar
• 12 Ståhl A L, Kristoffersson A, Olin A I et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.  Mol Immunol. 2009;  46(11-12) 2236-2243
  CrossrefPubMedGoogle Scholar
• 13 Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(4) 345-357
  CrossrefPubMedGoogle Scholar
• 14 Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.  Blood. 2010;  115(2) 379-387
  CrossrefPubMedGoogle Scholar
• 15 Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.  Blood. 2008;  111(3) 1512-1514
  CrossrefPubMedGoogle Scholar
• 16 Dragon-Durey M A, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(2) 555-563
  CrossrefPubMedGoogle Scholar
• 17 Frémeaux-Bacchi V, Miller E C, Liszewski M K et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.  Blood. 2008;  112(13) 4948-4952
  CrossrefPubMedGoogle Scholar
• 18 Goicoechea de Jorge E, Harris C L, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2007;  104(1) 240-245
  CrossrefPubMedGoogle Scholar
• 19 Caprioli J, Castelletti F, Bucchioni S International Registry of Recurrent and Familial HUS/TTP et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.  Hum Mol Genet. 2003;  12(24) 3385-3395
  CrossrefPubMedGoogle Scholar
• 20 Frémeaux-Bacchi V, Kemp E J, Goodship J A et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.  J Med Genet. 2005;  42(11) 852-856
  CrossrefPubMedGoogle Scholar
• 21 Blom A M, Bergström F, Edey M et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity.  J Immunol. 2008;  180(9) 6385-6391
  PubMedGoogle Scholar
• 22 Zipfel P F, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.  PLoS Genet. 2007;  3(3) e41
  CrossrefPubMedGoogle Scholar
• 23 Noris M, Remuzzi G. Hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(4) 1035-1050
  CrossrefPubMedGoogle Scholar
• 24 Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.  Pediatr Nephrol. 2003;  18(11) 1095-1101
  CrossrefPubMedGoogle Scholar
• 25 Ferraris J R, Ramirez J A, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.  Pediatr Nephrol. 2002;  17(10) 809-814
  CrossrefPubMedGoogle Scholar
• 26 Loirat C, Frémeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation.  Pediatr Transplant. 2008;  12(6) 619-629
  CrossrefPubMedGoogle Scholar
• 27 Bresin E, Daina E, Noris M International Registry of Recurrent and Familial HUS/TTP et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.  Clin J Am Soc Nephrol. 2006;  1(1) 88-99
  CrossrefPubMedGoogle Scholar
• 28 Sellier-Leclerc A L, Frémeaux-Bacchi V, Dragon-Durey M A French Society of Pediatric Nephrology et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2007;  18(8) 2392-2400
  CrossrefPubMedGoogle Scholar
• 29 Kavanagh D, Goodship T H. Membrane cofactor protein and factor I: mutations and transplantation.  Semin Thromb Hemost. 2006;  32(2) 155-159
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Schmidt C Q, Herbert A P, Kavanagh D et al. A new map of glycosaminoglycan and C3b binding sites on factor H.  J Immunol. 2008;  181(4) 2610-2619
  CrossrefPubMedGoogle Scholar
• 31 Ferreira V P, Herbert A P, Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.  J Immunol. 2009;  182(11) 7009-7018
  CrossrefPubMedGoogle Scholar
• 32 Lehtinen M J, Rops A L, Isenman D E, van der Vlag J, Jokiranta T S. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.  J Biol Chem. 2009;  284(23) 15650-15658
  CrossrefPubMedGoogle Scholar
• 33 Hirt-Minkowski P, Schaub S, Mayr M et al. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?.  Nephrol Dial Transplant. 2009;  24(11) 3548-3551
  CrossrefPubMedGoogle Scholar
• 34 Olie K H, Goodship T H, Verlaak R et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.  Am J Kidney Dis. 2005;  45(1) e12-e15
  CrossrefPubMedGoogle Scholar
• 35 Olie K H, Florquin S, Groothoff J W et al. Atypical relapse of hemolytic uremic syndrome after transplantation.  Pediatr Nephrol. 2004;  19(10) 1173-1176
  PubMedGoogle Scholar
• 36 Richards A, Kavanagh D, Atkinson J P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.  Adv Immunol. 2007;  96 141-177
  PubMedGoogle Scholar
• 37 Richards A, Kathryn Liszewski M, Kavanagh D et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.  Mol Immunol. 2007;  44(1-3) 111-122
  CrossrefPubMedGoogle Scholar
• 38 Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.  Am J Transplant. 2007;  7(8) 2047-2051
  CrossrefPubMedGoogle Scholar
• 39 Kavanagh D, Richards A, Noris M et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.  Mol Immunol. 2008;  45(1) 95-105
  CrossrefPubMedGoogle Scholar
• 40 Conway E M, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis.  Blood. 1993;  81(3) 726-733
  PubMedGoogle Scholar
• 41 Józsi M, Strobel S, Dahse H M et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.  Blood. 2007;  110(5) 1516-1518
  CrossrefPubMedGoogle Scholar
• 42 Le Quintrec M, Zuber J, Noel L H et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.  Am J Transplant. 2009;  9(5) 1223-1229
  CrossrefPubMedGoogle Scholar
• 43 Kwon T, Dragon-Durey M A, Macher M A et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome.  Nephrol Dial Transplant. 2008;  23(6) 2088-2090
  CrossrefPubMedGoogle Scholar
• 44 Donne R L, Abbs I, Barany P et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.  Am J Kidney Dis. 2002;  40(6) E22
  CrossrefPubMedGoogle Scholar
• 45 Bergstein J, Michael Jr A, Kellstrand C, Simmons R, Najarian J. Hemolytic-uremic syndrome in adult sisters.  Transplantation. 1974;  17(5) 487-490
  CrossrefPubMedGoogle Scholar
• 46 Kaplan B S, Papadimitriou M, Brezin J H, Tomlanovich S J, Zulkharnain. Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome.  Am J Kidney Dis. 1997;  30(6) 760-765
  CrossrefPubMedGoogle Scholar
• 47 Heinen S, Sanchez-Corral P, Jackson M S et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome.  Hum Mutat. 2006;  27(3) 292-293
  PubMedGoogle Scholar
• 48 Kavanagh D, Goodship T H, Richards A. Atypical haemolytic uraemic syndrome.  Br Med Bull. 2006;  77–78 5-22
  PubMedGoogle Scholar
• 49 Remuzzi G, Ruggenenti P, Codazzi D et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.  Lancet. 2002;  359(9318) 1671-1672
  CrossrefPubMedGoogle Scholar
• 50 Remuzzi G, Ruggenenti P, Colledan M et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation.  Am J Transplant. 2005;  5(5) 1146-1150
  CrossrefPubMedGoogle Scholar
• 51 Cheong H I, Lee B S, Kang H G et al. Attempted treatment of factor H deficiency by liver transplantation.  Pediatr Nephrol. 2004;  19(4) 454-458
  CrossrefPubMedGoogle Scholar
• 52 Saland J M, Emre S H, Shneider B L et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.  Am J Transplant. 2006;  6(8) 1948-1952
  CrossrefPubMedGoogle Scholar
• 53 Saland J M, Shneider B L, Bromberg J S et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2009;  4(1) 201-206
  CrossrefPubMedGoogle Scholar
• 54 Jalanko H, Peltonen S, Koskinen A et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.  Am J Transplant. 2008;  8(1) 216-221
  PubMedGoogle Scholar
• 55 Saland J M, Ruggenenti P, Remuzzi G. Consensus Study Group . Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2009;  20(5) 940-949
  CrossrefPubMedGoogle Scholar
• 56 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 542-544
  CrossrefPubMedGoogle Scholar
• 57 Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.  Am J Transplant. 2009;  9(11) 2644-2645
  CrossrefPubMedGoogle Scholar
• 58 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
  CrossrefPubMedGoogle Scholar
• 59 Kavanagh D, Richards A, Frémeaux-Bacchi V et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2007;  2(3) 591-596
  CrossrefPubMedGoogle Scholar
• 60 Ariceta G, Besbas N, Johnson S European Paediatric Study Group for HUS et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.  Pediatr Nephrol. 2009;  24(4) 687-696
  CrossrefPubMedGoogle Scholar

David Kavanagh

Institute of Human Genetics, International Centre for Life, Central Parkway

Newcastle upon Tyne, NE1 3BZ United Kingdom

Email: davidkavanagh@doctors.org.uk